Cantor Fitzgerald Estimates VKTX FY2026 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Viking Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the biotechnology company will post earnings per share of ($4.01) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Viking Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. During the same period last year, the firm earned ($0.26) EPS.

Several other brokerages have also recently weighed in on VKTX. Truist Financial reiterated a “buy” rating and issued a $75.00 target price (down from $95.00) on shares of Viking Therapeutics in a report on Monday, April 28th. HC Wainwright restated a “buy” rating and issued a $102.00 price objective on shares of Viking Therapeutics in a report on Thursday, April 24th. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a research note on Tuesday, April 8th. They issued a “neutral” rating and a $30.00 price objective for the company. Morgan Stanley dropped their target price on shares of Viking Therapeutics from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Finally, Scotiabank started coverage on shares of Viking Therapeutics in a research report on Thursday, February 13th. They set a “sector outperform” rating and a $102.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Viking Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $87.15.

Viking Therapeutics Stock Down 1.3%

Shares of NASDAQ:VKTX opened at $28.58 on Wednesday. The business’s 50 day moving average is $26.34 and its 200 day moving average is $32.37. The stock has a market cap of $3.21 billion, a P/E ratio of -28.58 and a beta of 0.65. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $81.73.

Hedge Funds Weigh In On Viking Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new position in shares of Viking Therapeutics in the fourth quarter worth $1,715,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Viking Therapeutics in the 4th quarter valued at $528,000. Van ECK Associates Corp increased its position in shares of Viking Therapeutics by 58.0% in the 4th quarter. Van ECK Associates Corp now owns 14,911 shares of the biotechnology company’s stock valued at $600,000 after acquiring an additional 5,475 shares during the period. Blue Trust Inc. raised its stake in Viking Therapeutics by 363.1% in the 4th quarter. Blue Trust Inc. now owns 1,885 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 1,478 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Viking Therapeutics in the 4th quarter worth $429,000. 76.03% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Sarah Kathryn Rouan acquired 1,240 shares of the business’s stock in a transaction dated Monday, March 31st. The shares were purchased at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the acquisition, the director now directly owns 1,240 shares in the company, valued at $29,946. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.